Physician profile
Daniel Todd Lybbert
NPI 1790279941
$5,251.74
in general payments reported to CMS, 2019-2025
15 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $12.76 · 2021: $630 · 2022: $277 · 2023: $354 · 2024: $2,140 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571 · Travel and Lodging: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.24 |
| Travel and Lodging | $843.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,691.59 | 2024-2025 | |
| Boston Scientific Corporation | $1,599.89 | 2019-2025 | Ams 700, Axonics, Ams 800 Artificial Urinary Sphincter |
| Olympus Corporation of The Americas | $687.29 | 2019 | |
| Urogen Pharma, INC. | $372.03 | 2021-2025 | Jelmyto |
| Procept Biorobotics Corporation | $252.06 | 2024-2025 | Aquabeam System |
| Olympus America INC. | $189.19 | 2019-2021 | |
| Valencia Technologies Corporation | $120.80 | 2024 | Ecoin Device Kit |
| Ethicon US, LLC | $108.48 | 2021 | |
| Ambu INC. | $92.28 | 2022 | |
| Antares Pharma, INC. | $50.00 | 2023 | Xyosted, Tlando |
| Janssen Biotech, INC. | $28.27 | 2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $16.46 | 2024 | Prolaris |
| Sumitomo Pharma America, INC. | $15.94 | 2024 | Gemtesa |
| Karl Storz Endoscopy-America | $14.70 | 2019 | |
| Cook Medical LLC | $12.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lybbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.